Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

OBJECTIVE: Avelumab (MSB0010718C) is a fully human anti-programmed cell death ligand 1(PD-L1) antibody against PD-L1 interactions and enhances immune activation against tumor cells in the meantime. Avelumab has been approved for locally advanced or metastatic urothelial cancer (mUC) after disease pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Qian, Zheng, Hanrui, Chen, Ye, Peng, Xingchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093135/
https://www.ncbi.nlm.nih.gov/pubmed/35570929
http://dx.doi.org/10.3389/fpubh.2022.837854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093135/
https://www.ncbi.nlm.nih.gov/pubmed/35570929
http://dx.doi.org/10.3389/fpubh.2022.837854

Ejemplares similares